AstraZeneca (AZN) halted its phase 3 trial for prostate cancer treatment Truqap based on the recommendation of an independent data monitoring committee.
The trial, which evaluated the efficacy and safety of Truqap in combination with docetaxel and androgen-deprivation therapy in patients with metastatic castration-resistant prostate cancer, was deemed unlikely to achieve the primary endpoints of radiographic progression-free survival and overall survival versus the comparator arm, AstraZeneca said Tuesday in a statement, citing the committee's recommendation.
Price: 70.59, Change: +0.66, Percent Change: +0.94
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.